All News
Filter News
Found 657 articles
-
Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization
11/2/2022
Actinium Pharmaceuticals, Inc. today announced the appointment of Caroline Yarbrough as Chief Commercial Officer.
-
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
10/31/2022
Actinium Pharmaceuticals, Inc. announced positive top-line results from the pivotal Phase 3 trial for its lead product candidate Iomab-B.
-
Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference
10/26/2022
Actinium Pharmaceuticals, Inc. today announced that it will be participating in the Bio-Europe conference being held virtually November 2 – 4, 2022.
-
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
10/25/2022
Actinium Pharmaceuticals, Inc. today highlighted multiple additions to its senior leadership team including Jenny Hsieh as Chief Strategy Officer, Sunitha Lakshminarayanan, as Senior Vice President, Head of CMC and Product Development, and Stephen Dressel as Vice President, Strategic Finance and Analysis.
-
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma
10/12/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that, as disclosed on uspto.gov, the United States Patent and Trademark Office (“USPTO”) has allowed U.S. Patent Application No. 17/720,619, titled “Use of Tivozanib to Treat Subjects with Refractory Cancer” (the “Application”).
-
Actinium to Present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
9/26/2022
Actinium Pharmaceuticals, Inc. today announced that it will present at the Cantor Fitzgerald Oncology, Hematology & HemOnc Conference, which is being held on September 28th at the Lotte New York Palace Hotel.
-
Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones
9/21/2022
On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from the Actimab-A CLAG-M combination trial expected in Q4 2022.
-
AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference
9/21/2022
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will participate in a panel discussion at the Cantor Fitzgerald Oncology & HemOnc Conference.
-
Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
9/8/2022
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will be participating in the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14, 2022.
-
AVEO Oncology Announces Participation at Investor Conferences in September
8/31/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of its senior management team are scheduled to participate in three investor conferences in September.
-
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/10/2022
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.
-
AVEO Oncology Reports Second Quarter 2022 Financial Results
8/4/2022
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reported financial results for the second quarter ended June 30, 2022.
-
AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022
7/28/2022
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022.
-
C-MET & HGF Inhibitors Market Size, Share, Growth, Trends, Report 2022-2030
7/12/2022
The global C-MET & HGF Inhibitors market size is estimated to be worth US$ 2294.7 million in 2021 and is forecast to a readjusted size of US$ 10450 million by 2030 with a CAGR of 23.9% during the forecast period 2022-2030.
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
6/22/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement in North America with Eli Lilly and Company (Lilly) to evaluate ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
-
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients
6/21/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines released on June 17, 2022.
-
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting
6/6/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology focused biopharmaceutical company, presented three posters during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting highlighting data for tivozanib, the Company’s oral, once-daily next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) designed to block the VEGF pathway by potently and selectively inhibiting all three VEGF receptors.
-
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
5/18/2022
AVEO Oncology announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. eastern time.
-
IMV Inc. Announces First Quarter 2022 Financial and Operational Results
5/13/2022
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the first quarter ended March 31, 2022.
-
AVEO Oncology Reports First Quarter 2022 Financial Results
5/5/2022
AVEO Oncology today reported financial results for the first quarter ended March 31, 2022.